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Systematic reviews attempt to answer a deﬁned question or
hypothesis through structured review of the evidence with a
methodology that is predeﬁned in a study protocol.
Meta-analysis is merely the statistical method used to compile
effect estimates from individual studies. Labelling studies as
‘meta-analysis’ is a misnomer, as would be labelling an
observational study ‘multivariate’, and the technical term
‘meta-analysis’ is not to be confused with the study design
‘systematic review’. Unfortunately, studies entitled ‘systematic
reviews’ do not always conform to the requisites of a
systematic review, and it is up to the reader to critically
appraise the review and decide whether it indeed provides a
systematic answer to the deﬁned question. In this theme issue,
we hope to provide readers with some tools to critically
appraise reviews using meta-analysis techniques.
The classic systematic review addresses a question on an
intervention; that is, is treatment A better than treatment B?
These are termed intervention reviews, and are usually limited
to randomized controlled trials (RCTs), as systematic reviews
attempt to provide unbiased answers. When no RCTs are
available (e.g. beneﬁt of appropriate empirical antibiotic
treatment for sepsis), systematic reviews might attempt to
analyse and compile results from observational studies [1]. A
systematic review and meta-analysis of observational data does
not solve the problem of selection bias. However, systematic
reviews of both RCTs and observational studies have tools
with which to systematically appraise the risk of bias. Using the
aggregate data, the systematic review can evaluate the effect of
bias on results, and through this possibly point at a truer effect
estimate than the individual studies. Leibovici et al. [2] highlight
the special features of systematic reviews in infectious
diseases.
Systematic reviews including network meta-analysis address
the broader question of which treatment is best, referring to
several treatments in a single review. The reader should
differentiate between direct comparisons based on RCTs and
indirect comparisons in the network that are, by nature,
observational (Fig. 1). The sources of bias in such comparisons
have yet to be deﬁned. Kanters et al. [3] present the network
of RCTs examining antiretroviral therapy for human immuno-
deﬁciency virus-na€ıve patients, highlighting the advantages of
network systematic reviews in identifying gaps in evidence.
Diagnostic test accuracy (DTA) systematic reviews sum-
marize data on the performance characteristics of a test. The
methods of DTA reviews and the statistical methods used to
compile diagnostic studies are evolving. The methods are more
complex than the meta-analysis of intervention studies, as a
test has two performance measures (sensitivity and speciﬁcity)
that are not independent. These reviews will become increas-
ingly common in infectious diseases and clinical microbiology.
Leeﬂang’s review presents an excellent introduction to DTA
reviews [4].
Clinicians are frequently uncomfortable with the ‘mix’ of
studies in a meta-analysis. A ﬁrst step in a systematic review is
to ask whether a priori compilation of the studies makes sense,
regardless of how the graph appears. For example, a review
addressing the question of whether iron increases the risk for
FIG. 1. Treatment network. A small network of four treatments
examined in randomized controlled trials (RCTs). The lines between
treatments represent comparisons that have been examined in RCTs,
and the number over the line represents the number of RCTs
examining the comparison. Comparisons between treatment A and
treatment B, between treatment B and treatment C and between
treatment C and treatment D are direct comparisons. An indirect
comparison between treatment A and treatment C could be derived
from the network. Treatment B had been compared with treat-
ment D, but only in a single trial. An indirect comparison between
treatment B and treatment D could include more trials. However,
indirect comparisons of RCTs are not randomized comparisons.
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malaria among children in malaria-endemic areas might include
all RCTs examining iron vs. no iron, with no other intervention
added. However, iron is often given together with other food
supplements or micronutrients; thus, to address the overall
evidence, the authors might also include studies comparing
iron + A vs. A, where A includes one or more micronutrients
but is identical in both arms. To be more comprehensive,
others might include all comparisons where an intervention
including iron was compared with an intervention without
iron, regardless of additional supplements in one or another
arm. Which of these comparisons is valid? Which would
provide the best information on whether iron can harm
children in malaria-endemic areas? The answer would entail
understanding whether the other micronutrients have an
effect on malaria and mortality. If we wish to be sure that the
other supplements have no effect on malaria, and our
hypothesis is that iron increases the risk for malaria, the third
comparison would best answer our question, as it would have
included more studies.
A glance at the meta-analysis forest plot might sometimes
give us more information on the presence of heterogeneity
than the statistical tests. Fig. 2a presents a meta-analysis where
the point estimates of the individual studies fall close together
and their 95% CIs overlap, so there is no signiﬁcant hetero-
geneity. The meta-analysis is helpful, because none of the
studies show a signiﬁcant difference between treatments, their
results are consistently in favour of treatment A with broad
CIs, and the meta-analysis shows a similar effect estimate with
narrow CIs and a signiﬁcant advantage for treatment A. If
combining the studies makes clinical sense, the combined point
estimate showing a signiﬁcant advantage for treatment A can
be trusted. Fig. 2b presents a totally unhelpful meta-analysis,
whether combining the studies a priori makes sense or not.
The point estimates of the different studies are very different,
and their 95% CIs do not overlap. In Fig. 2c, there is again
some heterogeneity on visual inspection of the graph, because
studies A and B do not overlap. However, all studies in this
graph show an advantage for treatment A, large or small, so
the pooled result is more credible than that of Fig. 2b.
Formally, heterogeneity is measured with statistical tests.
Melsen et al. show that these tests are unreliable when pooling
studies in a meta-analysis does not make clinical sense.
Of the methods to deal with heterogeneity, subgroup
analysis is most helpful clinically, as it can point to speciﬁc
patient or intervention characteristics in which the interven-
tion has an effect. In the above-mentioned review on the
effects of iron supplementation on malaria incidence among
children, signiﬁcant heterogeneity was observed. For readers, I
recommend asking which patient or intervention characteris-
tics might underlie different treatment effects and looking for
FIG. 2. Heterogeneity of meta-analyses of treatment A vs. treatment B. The risk ratio of individual studies is denoted by a blue square; its size is
proportional to the contribution (weight) of the study in the meta-analysis, and the line passing through it represents the study’s 95% CI. The pooled
result is represented by a black diamond, whose width represents the meta-analysis 95% CIs. Heterogeneity can be ﬁrst assessed through visual
inspection of the forest plots, and formally examined with the p-value for heterogeneity (p <0.1 conventionally denoting signiﬁcant heterogeneity) or
the I2 test (I2 > 50% denoting substantial heterogeneity). d.f., degrees of freedom; M-H, Mantel–Haenszel.
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these analyses in the systematic review. The systematic review
found that, in settings with adequate access to malaria
prevention and treatment, iron had no effect on malaria
incidence, whereas in settings where such treatment was not
offered to children, iron supplementation resulted in an
increased incidence of malaria (forest plot on cover image)
[5]. Thus, subgroup analysis can be directly translated to
clinical practice. A limitation of the review is that subgroup
analyses by baseline iron status and age group, analysing
children below 6 months of age separately, could not be
performed.
As more and more systematic reviews are published, we
encounter conﬂicting or otherwise discordant results from
different systematic reviews on the same topic. Examples in
infectious diseases include systematic reviews reporting con-
ﬂicting results regarding the effects of several interventions on
all-cause mortality, including cefepime for sepsis [6,7], tigecy-
cline [8–11], and selective digestive decontamination in
critically ill patients [12,13]. Multiple reviews on the same
topic frequently address slightly different questions, even if the
main question may appear identical. The patient population
addressed might be different, different outcomes might be
addressed (all-cause vs. infection-related mortality) or the
same outcomes deﬁned differently (in-hospital vs. 30-day
mortality; mortality by intention to treat or as-treated), and
the study design deﬁninitions for inclusion or the comprehen-
siveness of the search may result in the inclusion of a different
set of studies. Handling multiple systematic reviews on the
same topic entails critical reading of the different studies and
choosing the study most closely answering the relevant
question with the least bias.
Should systematic reviews with meta-analyses be consid-
ered as level I evidence? Systematic reviews with meta-analy-
ses might reveal results that were not and could not be
apparent in the individual RCT. An example is the systematic
review compiling all RCTs on antibiotic prophylaxis among
cancer patients showing that prophylaxis reduces all-cause
mortality [14]. Individual RCTs, even the most recent large
RCTs [15,16], were not powered to evaluate all-cause
mortality. Thus, well-conducted systematic reviews of ran-
domized controlled trials should be considered as level I
research evidence for guideline development or other
evidence appraisal. Meta-analyses that are not part of a
systematic review or that refer to a particular set of RCTs
might be considered level I or lower evidence, depending on
the context. Systematic review and meta-analyses of obser-
vational data should be considered at the level of observa-
tional data and graded within this evidence level by the risk of
bias in the analysis (compilation of adjusted or unadjusted
analysis and other criteria). Again, ranking the level of
evidence of a systematic review mandates critical appraisal
of the study.
Systematic reviews constitute a powerful tool with which to
examine treatment effects. Profound understanding of such
studies has become essential to sift through the vast body of
literature available. Critical reading will provide the clinician
with more information than the authors’ conclusions, and
solves many of the apparent inconsistencies between the
systematic review and the primary studies or between multiple
reviews.
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